Search

Your search keyword '"Riveline J"' showing total 167 results
Start Over Author "Riveline J"
167 results on '"Riveline J"'

2. Early macrophage response to obesity encompasses Interferon Regulatory Factor 5 regulated mitochondrial architecture remodelling

Author

Orliaguet, L., Ejlalmanesh, T., Humbert, A., Ballaire, R., Diedisheim, M., Julla, J. B., Chokr, D., Cuenco, J., Michieletto, J., Charbit, J., Lindén, D., Boucher, J., Potier, C., Hamimi, A., Lemoine, S., Blugeon, C., Legoix, P., Lameiras, S., Baudrin, L. G., Baulande, S., Soprani, A., Castelli, F. A., Fenaille, F., Riveline, J. P., Dalmas, E., Rieusset, J., Gautier, J. F., Venteclef, N., and Alzaid, F.

Published
2022
Full Text
View/download PDF

8. INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes

Author

Dunger, David B., Bruggraber, Sylvaine F. A., Mander, Adrian P., Marcovecchio, M. Loredana, Tree, Timothy, Chmura, Piotr Jaroslaw, Knip, Mikael, Schulte, Anke M., Mathieu, Chantal, Mathieu, C., Gillard, P., Casteels, K., Overbergh, L., Dunger, D., Wallace, C., Evans, M., Thankamony, A., Hendriks, E., Bruggraber, S., Peakman, M., Tree, T., Morgan, N., Richardson, S., Todd, J., Wicker, L., Mander, A., Dayan, C., Alhadj Ali, M., Pieber, T., Eizirik, D., Cnop, M., Brunak, S., Pociot, F., Johannesen, J., Rossing, P., Legido Quigley, C., Mallone, R., Scharfmann, R., Boitard, C., Knip, M., Otonkoski, T., Veijola, R., Lahesmaa, R., Oresic, M., Toppari, J., Danne, T., Ziegler, A. G., Achenbach, P., Rodriguez-Calvo, T., Solimena, M., Bonifacio, E., Speier, S., Holl, R., Dotta, F., Chiarelli, F., Marchetti, P., Bosi, E., Cianfarani, S., Ciampalini, P., de Beaufort, C., Dahl-Jørgensen, K., Skrivarhaug, T., Joner, G., Krogvold, L., Jarosz-Chobot, P., Battelino, T., Thorens, B., Gotthardt, M., Roep, B., Nikolic, T., Zaldumbide, A., Lernmark, A., Lundgren, M., Costecalde, G., Strube, T., Schulte, A., Nitsche, A., von Herrath, M., Wesley, J., Napolitano-Rosen, A., Thomas, M., Schloot, N., Goldfine, A., Waldron-Lynch, F., Kompa, J., Vedala, A., Hartmann, N., Nicolas, G., van Rampelbergh, J., Bovy, N., Dutta, S., Soderberg, J., Ahmed, S., Martin, F., Agiostratidou, G., Koralova, A., Willemsen, R., Smith, A., Anand, B., Puthi, V., Zac-Varghese, S., Datta, V., Dias, R., Sundaram, P., Vaidya, B., Patterson, C., Owen, K., Piel, B., Heller, S., Randell, T., Gazis, T., Bismuth Reismen, E., Carel, J-C, Riveline, J-P, Gautier, J-F, Andreelli, F., Travert, F., Cosson, E., Penfornis, A., Petit, C., Feve, B., Lucidarme, N., Beressi, J-P, Ajzenman, C., Radu, A., Greteau-Hamoumou, S., Bibal, C., Meissner, T., Heidtmann, B., Toni, S., Rami-Merhar, B., Eeckhout, B., Peene, B., Vantongerloo, N., Maes, T., Gommers, L., Marcovecchio, M.L., Vela, J., Latres, E., Children's Hospital, and HUS Children and Adolescents

Subjects
Trials, Adult, Adolescent, SARS-CoV-2, Prevention, Beta-cell function, COVID-19, Medicine (miscellaneous), Beta-cell Function, C-peptide, Master Protocol, Phase 2, Type 1 Diabetes, Type 1 diabetes, Diabetes Mellitus, Type 1, Treatment Outcome, 3121 General medicine, internal medicine and other clinical medicine, Diabetes Mellitus, Type 1/diagnosis, Master protocol, Humans, Pharmacology (medical), Child, Biomarkers
Abstract

Background The INNODIA consortium has established a pan-European infrastructure using validated centres to prospectively evaluate clinical data from individuals with newly diagnosed type 1 diabetes combined with centralised collection of clinical samples to determine rates of decline in beta-cell function and identify novel biomarkers, which could be used for future stratification of phase 2 clinical trials. Methods In this context, we have developed a Master Protocol, based on the “backbone” of the INNODIA natural history study, which we believe could improve the delivery of phase 2 studies exploring the use of single or combinations of Investigational Medicinal Products (IMPs), designed to prevent or reverse declines in beta-cell function in individuals with newly diagnosed type 1 diabetes. Although many IMPs have demonstrated potential efficacy in phase 2 studies, few subsequent phase 3 studies have confirmed these benefits. Currently, phase 2 drug development for this indication is limited by poor evaluation of drug dosage and lack of mechanistic data to understand variable responses to the IMPs. Identification of biomarkers which might permit more robust stratification of participants at baseline has been slow. Discussion The Master Protocol provides (1) standardised assessment of efficacy and safety, (2) comparable collection of mechanistic data, (3) the opportunity to include adaptive designs and the use of shared control groups in the evaluation of combination therapies, and (4) benefits of greater understanding of endpoint variation to ensure more robust sample size calculations and future baseline stratification using existing and novel biomarkers.

Published
2022

21. The Clinical Variability of Maternally Inherited Diabetes and Deafness Is Associated with the Degree of Heteroplasmy in Blood Leukocytes

Author

Laloi-Michelin, M, Meas, T, Ambonville, C, Bellanné-Chantelot, C, Beaufils, S, Massin, P, Vialettes, B, Gin, H, Timsit, J, Bauduceau, B, Bernard, L, Bertin, E, Blickle, J -F., Cahen-Varsaux, J, Cailleba, A, Casanova, S, Cathebras, P, Charpentier, G, Chedin, P, Crea, T, Delemer, B, Dubois-Laforgue, D, Duchemin, F, Ducluzeau, P H., Bouhanick, B, Dusselier, L, Gabreau, T, Grimaldi, A, Guerci, B, Jacquin, V, Kaloustian, E, Larger, E, Lecleire-Collet, A, Lorenzini, F, Louis, J, Mausset, J, Murat, A, Nadler-Fluteau, S, Olivier, F, Paquis-Flucklinger, V, Paris-Bockel, D, Raynaud, I, Reznik, Y, Riveline, J P., Schneebeli, S, Sonnet, E, Sola-Gazagnes, A, Thomas, J L., Trabulsi, B, Virally, M, and Guillausseau, P J.

Published
2009

31. New insights on the Marseille-Aubagne Oligocene basins (France)

Author

Nury, D., Villeneuve, M., Arlhac, P., Gartner, A., Linnemann, U., Chateauneuf, J. J., Riveline, J., Hippolyte, J. C., Centre européen de recherche et d'enseignement des géosciences de l'environnement (CEREGE), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Collège de France (CdF)-Institut national des sciences de l'Univers (INSU - CNRS)-Aix Marseille Université (AMU)-Institut National de la Recherche Agronomique (INRA), Aix Marseille Université (AMU)-Institut national des sciences de l'Univers (INSU - CNRS)-Collège de France (CdF (institution))-Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Recherche Agronomique (INRA), Beaussier, Catherine, and Institut de Recherche pour le Développement (IRD)-Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Collège de France (CdF (institution))-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Marseille-Aubagne basins, Western European rift, rifting del Mediterráneo, Western Mediterranean rifting, cuencas de Marsella-Aubagne, rift de Eupora occidental, oligocene, oligoceno, occidental, [SDU.STU] Sciences of the Universe [physics]/Earth Sciences, [SDU.STU]Sciences of the Universe [physics]/Earth Sciences
Abstract

Las cuencas de Marsella-Aubagne, que se extienden desde Marsella a Roquevaire, ocupan más del cin¬cuenta por ciento del mapa geológico de Marsella-Aubagne con cerca de un millón de personas viviendo en la región. A pesar de su importancia geológica, aún son poco conocidas. La primera visión sintética fue llevada a cabo en el mapa geológico de 1935. Estudiados por Bonifay, los depósitos cuaternarios fueron incluidos en el mapa geológico de 1969. Sin embargo, las formaciones del Oligoceno no se modificaron hasta que Nury proporcionó una gran cantidad de datos estratigráficos muy detallados. Nuevos estudios han sido llevados a cabo en el marco de la tercera edición del mapa geológico 1:50 000. Estos estudios per¬miten distinguir entre tres cuencas diferentes: la «cuenca de Jarret» en la parte norte, la «cuenca del Prado» en la parte suroeste y la «cuenca de Aubagne» en la parte oriental. Cada una de ellas contiene su propia sucesión estratigráfica que incluye varias formaciones desde el Rupeliense hasta el Chattiense. De manera general, las formaciones del Rupeliense inferior a superior están deformadas tectónicamente, mientras que los depósitos del final del Rupeliense hasta el Chattiense superior sólo presentan una deformación leve. Por lo tanto, se han podido diferenciar dos etapas geodinámicas principales: la primera empieza con régimen distensivo en el Oligoceno inferior y conduce a la apertura de depresiones de dirección NNE-SSO a lo largo de toda la plataforma europea y, la segunda, que comienza con un régimen distensivo NNO-SSE coetáneo con el rifting del Mediterráneo Occidental. El punto clave que separa estas dos fases entre sí es un posible régimen compresivo en el Rupeliense más tardío. Para concluir, esta cuenca se puede utilizar como un archi¬vo natural para los eventos del Oligoceno. Por lo tanto, estas cuencas deben ser consideradas como piezas maestras para las reconstrucciones paleogeográficas y geodinámicas del Oligoceno. The Marseille-Aubagne Basins, which extend from Marseille to Roquevaire, occupy more than fifty per cent of the Marseille-Aubagne geological map, with approximately one million people living in this area. Despite this geological importance they are still poorly known. The first synthetic view was delivered in the 1935 geological map. Studied by Bonifay, the Quaternary deposits have been included in the 1969 geological map. Nevertheless, the Oligocene formations remained unmodified until Nury, who provided a lot of very detailed stratigraphic data. New studies have been carried out in the frame of the third issue of the 1:50,000 geological map. These studies allow us to distinguish between three different basins: the “Jarret basin” in the northern part, the “Prado basin” in the southwestern part and the “Aubagne basin” in the eastern part. Each of them contains its own stratigraphic succession, including several formations from the Rupelian to the Chattian. Globally, the Lower to Upper Rupelian formations are tectonically deformed, whilst deposits from the Latest Rupelian to the Latest Chattian show only slight deformation. Thus, two main geodynamic stages have been distinguished: the first beginning with the Early Oligocene extensive regime leading to the opening of NNE-SSW troughs all over the European platform and, the second, beginning with a NNW-SSE extensive regime coeval with the Western Mediterranean rifting. The key point that separates these two stages from each other is a possible Late Rupelian compressive regime. To sum up, this basin can be considered as a natural archive for the Oligocene events. Therefore, these basins should be considered as master pieces for the Oligocene palaeogeographic and geodynamic reconstructions.

Published
2016

33. Éducation à l’utilisation pratique et à l’interprétation de la Mesure Continue du Glucose : position d’experts français

Author

Hanaire, H., primary, Atlan, C., additional, Benhamou, P.-Y., additional, Bismuth, E., additional, Bonnemaison, E., additional, Borot, S., additional, Catargi, B., additional, Charpentier, G., additional, Farret, A., additional, Filhol, N., additional, Franc, S., additional, Gouet, D., additional, Guerci, B., additional, Guilhem, I., additional, Guillot, C., additional, Jeandidier, N., additional, Joubert, M., additional, Melki, V., additional, Merlen, E., additional, Penfornis, A., additional, Picard, S., additional, Renard, E., additional, Reznik, Y., additional, Riveline, J.-P., additional, Rudoni, S., additional, Schaepelynck, P., additional, Sola-Gazagnes, A., additional, Tubiana, N., additional, and Verier-Mine, O., additional

Published
2017
Full Text
View/download PDF

34. An Unsafe/Safe Typology in People with Type 2 Diabetes: Bridging Patients’ Expectations, Personality Traits, Medication Adherence, and Clinical Outcomes

Author

Reach G, Benarbia L, Benhamou PY, Delemer B, Dubois S, Gouet D, Guerci B, Jeandidier N, Lachgar K, Le Pape G, Leroy R, Masgnaux JH, Raclet P, Reznik Y, Riveline JP, Schaepelynck P, Vambergue A, and Vergès B

Subjects
type 2 diabetes, adherence, support programs, typology, personality traits, clinical outcomes, patients’ expectations, Medicine (General), R5-920
Abstract

Gérard Reach,1 Laurent Benarbia,2 Pierre-Yves Benhamou,3 Brigitte Delemer,4 Séverine Dubois,5 Didier Gouet,6 Bruno Guerci,7 Nathalie Jeandidier,8 Karim Lachgar,9 Gilles Le Pape,10 Rémy Leroy,11 Jean-Hugues Masgnaux,12 Philippe Raclet,13 Yves Reznik,14 Jean-Pierre Riveline,15,16 Pauline Schaepelynck,17 Anne Vambergue,18 Bruno Vergès19 1Health Education and Promotion Laboratory (LEPS EA 3412), Sorbonne Paris Nord University, Bobigny, France; 2Marketing Studio, Paris, France; 3Department of Endocrinology, Grenoble University Hospital; Grenoble Alpes University, INSERM U1055, LBFA, Grenoble, France; 4Service d’Endocrinologie – Diabète – Nutrition, CHU de Reims - Hôpital Robert Debré, and Université de Reims Champagne Ardenne, UFR Sciences Exactes Et Naturelles, Reims, France; 5Department of Diabetology and Endocrinology, CHU Angers, Angers, France; 6Department of Diabetology and Endocrinology, Saint Louis Hospital, La Rochelle, France; 7Department of Endocrinology, Diabetology and Nutrition, CHRU of Nancy, Brabois Hospital, and ILCV Lorraine University, Vandoeuvre-les-Nancy, France; 8Department of Endocrinology, Diabetes and Nutrition, Hôpitaux Universitaires de Strasbourg, and Université de Strasbourg, Strasbourg, France; 9Department of Diabetology and Endocrinology, Centre Hospitalier Simone Veil, Eaubonne, France; 10General Practice, Penmarc’h, France; 11Private Medical Practice, Endocrinology and Diabetology, Lille, France; 12M&M Conseil, Boulogne, France; 13Association Française des Diabétiques de Bourgogne Franche-Comté, Dijon, France; 14Department oEndocrinology and Diabetology, CHU Côte de Nacre, Caen, and University of Caen Basse-Normandie, Medical School, Caen, France; 15Department of Diabetology and Endocrinology, Lariboisière Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France; 16Unité INSERM U1138 Immunity and Metabolism in Diabetes, ImMeDiab Team, Centre de Recherches des Cordeliers, and Université de Paris, Paris, France; 17Department of Nutrition-Endocrinology-Metabolic Diseases, Pôle ENDO, APHM-Hôpital la Conception, Marseille, France; 18Department of Diabetology, Endocrinology, Metabolism and Nutrition, CHU Lille, and University Hospital European Genomic Institute for Diabetes, Lille, France; 19Department of Endocrinology-Diabetology,CHU Dijon, and University of Burgundy, INSERM LNC UMR1231, Dijon, FranceCorrespondence: Gérard Reach, Health Education and Promotion Laboratory (LEPS EA 3412), Sorbonne Paris Nord University, 74 Rue Marcel Cachin, Bobigny Cedex, 93017, France, Tel + 33 (0)6 60 84 53 25, Email gerardreach@icloud.comBackground: Support programs are provided to people with diabetes to help them manage their disease. However, adherence to and persistence in support programs are often low, making it difficult to demonstrate their effectiveness.Aim: To identify the determinants of patients’ perceived interest in diabetes support programs because it may be a powerful determinant of effective participation in such programs.Patients and Methods: An online study conducted in April 2021 in metropolitan France on 600 people with diabetes recruited from a consumer panel. A 64-item psychosocial questionnaire including a question asking to evaluate the helpfulness of a support program was used. Univariate, multivariate, and multiple correspondence analyses were performed.Results: The existence of a typology, known as Unsafe/Safe, was discovered, in which patients with type 2 diabetes respond in two distinct ways. Type U (unsafe) patients, who believe that a support program would be helpful, are more likely to be nonadherent to their treatment, have high hemoglobin A1c levels, have at least one diabetic complication, lack information regarding their disease and treatment, rate the burden of their disease and impairment of their quality of life as high, worry about their future, and are pessimistic. Type S (safe) patients have the opposite characteristics. Type U patients can be dichotomized into two broad classes: one in which they lack information regarding disease and treatment and the other in which alterations in the quality of life and burden of the disease predominate. Insulin-treated patients give more importance to the lack of information, whereas noninsulin-treated patients complain primarily about the burden of the disease and impairment of quality of life.Conclusion: This study describes this new U/S typology, proposes a simple method based on a nine-item questionnaire to identify type U patients by calculating a Program Helpfulness Score described herein, and clarifies the nature of the intervention to be provided to them. This novel approach could be applied to other chronic diseases.Keywords: type 2 diabetes, adherence, support programs, typology, personality traits, clinical outcomes, patients’ expectations

Published
2022

38. CO-24: Les objectifs de LDL-cholestérol des recommandations européennes sont-ils respectés chez les diabétiques ? Évaluation d'une cohorte suivie dans une structure ambulatoire multidisciplinaire

Author

Vidal-trécan, T., primary, Bouché, C., additional, Dillinger, J., additional, Kevorkian, J., additional, Laloi-michelin, M., additional, Feron, F., additional, Salle, L., additional, Juddoo, V., additional, Race, J., additional, Baz, B., additional, Sarron, T., additional, Samuel-Lajeunesse, J., additional, Bouallouche, A., additional, Leblanc, H., additional, Gautier, J., additional, Henry, P., additional, and Riveline, J., additional

Published
2016
Full Text
View/download PDF

41. Regulation of mass and function of beta cells by glucocorticoids: implication of serotonin

Author

Riveline, J. P., Massourides, E., Singh-Estivalet, A., Valtat, B., Armanet, M., Callebert, J., Bailly, A., Benecke, A., Tronche, F., Gautier, J. F., Breant, B., Blondeau, B., Expression des Gènes et comportement adaptatifs = Molecular Genetics, Neurophysiology and Behavior (NPS-15), Neuroscience Paris Seine (NPS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Biologie Paris Seine (IBPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Biologie Paris Seine (IBPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Neurosciences Paris Seine (NPS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Biologie Paris Seine (IBPS), and Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], ComputingMilieux_MISCELLANEOUS
Abstract

International audience; no abstract

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results